F-Prime Capital

1upHealth, Inc. is a health data aggregation and centralization company based in Boston, Massachusetts, founded in 2017. It operates a platform that enables patients, providers, and software developers to securely aggregate and share medical data from various electronic medical record systems. The platform consolidates health data into a digital health record that users can control and share with healthcare providers. It facilitates real-time access to updated patient information across multiple health systems, enhancing the ability of providers to deliver informed care. Additionally, the platform automates secure data sharing from electronic medical records and wearable device metrics, allowing for improved healthcare outcomes through a trusted interoperability network.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

Funnel is a software company that specializes in marketing analytics and reporting tools designed to streamline data collection for online advertisers and e-commerce businesses. Founded in 2014 by Fredrik Skantze and Per Made, the company is headquartered in Stockholm and has an office in Boston. Funnel offers a platform that integrates seamlessly with over 400 marketing and advertising data sources, enabling users to automate the collection and organization of their advertising performance data. This integration allows businesses to easily transfer their data into various tools, such as Business Intelligence platforms, Data Warehouses, Google Sheets, and visualization tools. By providing a comprehensive overview of advertising expenditures and performance, Funnel helps businesses, including e-commerce companies, media agencies, B2B enterprises, mobile applications, and gaming firms, make informed decisions and predict future growth.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

1upHealth, Inc. is a health data aggregation and centralization company based in Boston, Massachusetts, founded in 2017. It operates a platform that enables patients, providers, and software developers to securely aggregate and share medical data from various electronic medical record systems. The platform consolidates health data into a digital health record that users can control and share with healthcare providers. It facilitates real-time access to updated patient information across multiple health systems, enhancing the ability of providers to deliver informed care. Additionally, the platform automates secure data sharing from electronic medical records and wearable device metrics, allowing for improved healthcare outcomes through a trusted interoperability network.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

RightHand Robotics, Inc. is a manufacturer of robotic order-picking systems that streamline supply chain logistics for various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company specializes in robotic solutions that automatically grasp a wide variety of items from bins and cases. Its flagship products include the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor designed to enhance the robots' ability to handle items gently and correct errors. RightHand Robotics focuses on providing end-to-end solutions that simplify integration and adaptation to diverse customer workflows, ultimately reducing the costs associated with order fulfillment across sectors such as electronics, apparel, grocery, and pharmaceuticals.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Funnel is a software company that specializes in marketing analytics and reporting tools designed to streamline data collection for online advertisers and e-commerce businesses. Founded in 2014 by Fredrik Skantze and Per Made, the company is headquartered in Stockholm and has an office in Boston. Funnel offers a platform that integrates seamlessly with over 400 marketing and advertising data sources, enabling users to automate the collection and organization of their advertising performance data. This integration allows businesses to easily transfer their data into various tools, such as Business Intelligence platforms, Data Warehouses, Google Sheets, and visualization tools. By providing a comprehensive overview of advertising expenditures and performance, Funnel helps businesses, including e-commerce companies, media agencies, B2B enterprises, mobile applications, and gaming firms, make informed decisions and predict future growth.

Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York City. Founded in 2014, Buoy Health develops an artificial intelligence-driven digital health solution designed to empower individuals in managing their health and navigating the healthcare system. The company's primary offering, Buoy Health, is an online healthcare chatbot that provides personalized symptom analysis, facilitates first-line triage, and offers treatment recommendations. This platform functions as a comprehensive resource, enabling users to engage in self-diagnosis and access information about health benefits. Additionally, Buoy Health can be customized for employers to help employees find in-network providers and access wellness programs, thereby enhancing the overall healthcare experience.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, focused on developing technologies that promote efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and Mobility-on-Demand Systems. Optimus Ride specializes in creating self-driving technology systems tailored for geofenced environments, utilizing innovations in complex sensor fusion, mapping, computer vision, and machine learning. The company's expertise is further enhanced by a team with extensive industrial and entrepreneurial experience in manufacturing robots, urban design, and shared vehicle fleet management, allowing it to offer versatile transportation solutions that range from commercial vessel operations to transit options.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it has developed a comprehensive digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform offers tailored programs, performance coaching, and research-based exercises aimed at fostering peak performance. Additionally, Valor Performance provides progress metrics and a community focused on continuous improvement, ensuring a premium coaching experience that remains scalable. The company is dedicated to bridging the professional training gap through its innovative solutions.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, focused on developing technologies that promote efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and Mobility-on-Demand Systems. Optimus Ride specializes in creating self-driving technology systems tailored for geofenced environments, utilizing innovations in complex sensor fusion, mapping, computer vision, and machine learning. The company's expertise is further enhanced by a team with extensive industrial and entrepreneurial experience in manufacturing robots, urban design, and shared vehicle fleet management, allowing it to offer versatile transportation solutions that range from commercial vessel operations to transit options.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it has developed a comprehensive digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform offers tailored programs, performance coaching, and research-based exercises aimed at fostering peak performance. Additionally, Valor Performance provides progress metrics and a community focused on continuous improvement, ensuring a premium coaching experience that remains scalable. The company is dedicated to bridging the professional training gap through its innovative solutions.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York City. Founded in 2014, Buoy Health develops an artificial intelligence-driven digital health solution designed to empower individuals in managing their health and navigating the healthcare system. The company's primary offering, Buoy Health, is an online healthcare chatbot that provides personalized symptom analysis, facilitates first-line triage, and offers treatment recommendations. This platform functions as a comprehensive resource, enabling users to engage in self-diagnosis and access information about health benefits. Additionally, Buoy Health can be customized for employers to help employees find in-network providers and access wellness programs, thereby enhancing the overall healthcare experience.

Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing novel immunotherapies for cancer treatment, with a focus on CpG oligonucleotides. These oligonucleotides activate an anti-tumor T-cell response and are combined with checkpoint inhibition to enhance the immune system's ability to combat tumors. Checkmate Pharmaceuticals has formed strategic alliances with Merck KGaA and Pfizer to advance its clinical programs, aiming to increase the efficacy of existing immunotherapies and provide new treatment options for cancer patients.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Codeship Inc. is a provider of hosted continuous integration solutions, specializing in the development and deployment of Docker-based applications. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Vienna, Austria, the company was previously known as Railsonfire Limited before rebranding in January 2013. Codeship's platform is designed to streamline the software development process by automating testing and release tasks, which helps reduce development cycles, minimize the risk of bugs, and foster innovation. As of February 2018, Codeship operates as a subsidiary of CloudBees, Inc. The platform caters specifically to software companies, enabling them to enhance their product development efficiency through a customizable and scalable continuous integration and deployment service.

Toast, Inc. is a Boston-based restaurant technology company that specializes in developing an all-in-one point-of-sale and restaurant management platform tailored for the food service and hospitality industries. Founded in 2011, Toast offers a cloud-based system designed specifically for restaurants, enabling functionalities such as tableside ordering, real-time reporting, online ordering, and labor management. The platform serves a diverse clientele, including restaurants, cafés, bars, and bakeries, and supports over 120,000 locations across the United States. Toast generates revenue through software subscription fees, transaction processing commissions, and additional services such as hardware installation and professional support. By facilitating payment transactions on its platform, Toast processed approximately $126 billion in gross volume in 2023, demonstrating its significant role in the restaurant technology landscape.

Codeship Inc. is a provider of hosted continuous integration solutions, specializing in the development and deployment of Docker-based applications. Founded in 2011 and headquartered in Boston, Massachusetts, with an additional office in Vienna, Austria, the company was previously known as Railsonfire Limited before rebranding in January 2013. Codeship's platform is designed to streamline the software development process by automating testing and release tasks, which helps reduce development cycles, minimize the risk of bugs, and foster innovation. As of February 2018, Codeship operates as a subsidiary of CloudBees, Inc. The platform caters specifically to software companies, enabling them to enhance their product development efficiency through a customizable and scalable continuous integration and deployment service.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, specializing in the development of advanced intravenous (IV) infusion systems. Founded in 2001 and originally known as Fluidnet Corporation, Ivenix offers a next-generation infusion management platform that utilizes pneumatic technology to enhance the accuracy of fluid delivery. This innovative system is designed to measure and control flow regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. Additionally, the platform manages patient infusion data and integrates seamlessly with clinical information systems, ensuring precise and continuous infusion delivery in hospital settings. Ivenix aims to revolutionize infusion therapy worldwide by combining state-of-the-art information technology with user-friendly design, thereby improving patient care and safety.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company based in Cambridge, Massachusetts, focused on developing innovative cancer therapies. The company specializes in creating human immunoglobulin isotype G4 monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, which targets CD73; SRF617, which inhibits CD39; SRF388, aimed at interleukin 27; and SRF813, which targets CD112R. Additionally, Surface Oncology is advancing several preclinical programs that address other critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established strategic collaborations with Novartis Institutes for Biomedical Research and Merck Sharp & Dohme Corp. to advance the development of its therapies, including evaluating the combination of SRF617 with Merck’s KEYTRUDA. Founded in 2014, Surface Oncology aims to leverage novel immunotherapy targets and insights into cancer immuno-biology to enhance anti-tumor immune responses.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Kensho Technologies, Inc. is a provider of advanced analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. The company develops Kensho Financial Analytics Software, which delivers scalable analytical solutions to enhance decision-making within commercial entities. Kensho's offerings also include the Kensho Applied Mind, a sophisticated AI software that enables natural language processing to address complex financial inquiries in plain English. Additionally, Kensho operates a national security division known as Koto. Founded in 2012 and headquartered in Cambridge, Massachusetts, Kensho has expanded its presence with offices in New York, McLean, and Pacific Palisades. As of April 2018, Kensho Technologies operates as a subsidiary of S&P Global Inc.

ownCloud, Inc. is a software company that specializes in developing a universal file access platform designed for secure data storage and collaboration. Founded in 2011 and headquartered in Lexington, Massachusetts, with additional international presence in Germany, the company provides a self-hosted file sync and share server. This platform allows organizations to access, manage, and share files across various devices, utilizing their own data centers or cloud storage while ensuring compliance with regulatory standards. ownCloud offers solutions that include desktop clients for Windows, Mac OS, and Linux, as well as mobile applications, enabling seamless collaboration among users. The company's services cater to various industries, including financial services, healthcare, government, and education, enabling them to maintain control over their data while facilitating efficient content collaboration. As the most downloaded open-source project for file sync and share, ownCloud emphasizes flexibility and security in data management.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Kensho Technologies, Inc. is a provider of advanced analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. The company develops Kensho Financial Analytics Software, which delivers scalable analytical solutions to enhance decision-making within commercial entities. Kensho's offerings also include the Kensho Applied Mind, a sophisticated AI software that enables natural language processing to address complex financial inquiries in plain English. Additionally, Kensho operates a national security division known as Koto. Founded in 2012 and headquartered in Cambridge, Massachusetts, Kensho has expanded its presence with offices in New York, McLean, and Pacific Palisades. As of April 2018, Kensho Technologies operates as a subsidiary of S&P Global Inc.

Cloudant is a provider of distributed database-as-a-service (DBaaS) that enables developers of web and mobile applications to concentrate on product development without the complexities of database management and scaling. Founded in 2008 in Cambridge, Massachusetts, by three physicists from MIT, Cloudant was born out of a need for better tools to manage and analyze large datasets encountered in their research. The company built a fault-tolerant and globally scalable data layer on top of Apache CouchDB, addressing the challenges of handling Big Data. Since its inception, Cloudant has expanded its services and now supports thousands of developers and numerous clients worldwide by managing and serving application data efficiently.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

Cloudant is a provider of distributed database-as-a-service (DBaaS) that enables developers of web and mobile applications to concentrate on product development without the complexities of database management and scaling. Founded in 2008 in Cambridge, Massachusetts, by three physicists from MIT, Cloudant was born out of a need for better tools to manage and analyze large datasets encountered in their research. The company built a fault-tolerant and globally scalable data layer on top of Apache CouchDB, addressing the challenges of handling Big Data. Since its inception, Cloudant has expanded its services and now supports thousands of developers and numerous clients worldwide by managing and serving application data efficiently.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Iora Health, Inc. is a healthcare organization based in Boston, Massachusetts, that specializes in providing primary care services across the United States. Founded in 2010, Iora Health focuses on redesigning primary care to eliminate barriers and enhance patient experience. Each patient is assigned a personal physician and a health coach, ensuring continuous support and communication through various channels, including email, text, and video, in addition to in-person visits. The company employs a team-based approach to care, which includes a doctor or nurse practitioner, a nurse, a behavioral health specialist, and a health coach, all supported by a proprietary technology platform that integrates population health management into the primary care workflow. Iora Health also offers educational programs, such as group visits, to help patients stay engaged with their health and achieve their wellness goals.

FoldRx Pharmaceuticals, Inc. is engaged in the discovery and development of disease-modifying drug therapies targeting diseases caused by protein misfolding and amyloidosis. Based in Cambridge, Massachusetts, the company focuses on addressing conditions related to the accumulation of misfolded proteins, which can result from genetic mutations or defects in cellular quality control mechanisms. Its pipeline includes advanced clinical programs aimed at treating transthyretin-associated amyloidoses, specifically those affecting the nervous and cardiovascular systems. Additionally, FoldRx is exploring therapeutic options for Parkinson's disease and cystic fibrosis. Founded in 2003, the company aims to provide healthcare professionals with effective treatments for these complex conditions.

Bikam Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in the development of novel therapeutics aimed at treating degenerative diseases, particularly retinal disorders. It focuses on creating small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins in the retina, which are implicated in serious conditions such as retinitis pigmentosa and dry age-related macular degeneration. Bikam Pharmaceuticals has developed an orally active pharmacological chaperone that effectively binds to misfolded rod opsin, a protein associated with retinitis pigmentosa, and facilitates its proper trafficking to the surface of rod cells, thereby aiming to mitigate the effects of this rare and incurable genetic disease that leads to blindness.

FoldRx Pharmaceuticals, Inc. is engaged in the discovery and development of disease-modifying drug therapies targeting diseases caused by protein misfolding and amyloidosis. Based in Cambridge, Massachusetts, the company focuses on addressing conditions related to the accumulation of misfolded proteins, which can result from genetic mutations or defects in cellular quality control mechanisms. Its pipeline includes advanced clinical programs aimed at treating transthyretin-associated amyloidoses, specifically those affecting the nervous and cardiovascular systems. Additionally, FoldRx is exploring therapeutic options for Parkinson's disease and cystic fibrosis. Founded in 2003, the company aims to provide healthcare professionals with effective treatments for these complex conditions.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. The company utilizes its proprietary Dolaflexin platform to create a pipeline of novel ADC candidates designed to improve treatment outcomes for those not responding to traditional therapies. Mersana's lead product candidate, XMT-1536, targets NaPi2b and is currently undergoing Phase I clinical trials for ovarian cancer, non-small cell lung cancer, and other orphan indications. In addition to XMT-1536, the company is advancing several early-stage programs, including XMT-1660, which targets B7-H4, and XMT-2056, a STING agonist ADC. Mersana has established strategic partnerships for research and development, notably with Merck KGaA and Asana BioSciences, to enhance its ADC product portfolio. Founded in 2005, Mersana Therapeutics continues to innovate in the field of oncology therapeutics.

Ironwood Pharmaceuticals, Inc. is a healthcare company dedicated to the development and commercialization of gastrointestinal products. It is best known for its flagship product, linaclotide, which is used to treat adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. This medication is marketed as LINZESS in the United States and CONSTELLA in Canada and the European Union. Additionally, Ironwood is advancing other treatments, such as MD-7246, an oral pain reliever for abdominal pain associated with gastrointestinal diseases, and IW 3718, a formulation in Phase III clinical trials for gastroesophageal reflux disease. The company has established collaboration agreements with Allergan and AstraZeneca for the development of linaclotide in several regions, and a license agreement with Astellas Pharma for its use in Japan. Founded in 1998 and formerly known as Microbia, Inc., Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.